Evidence map›Paper›PMID 40062119›Full record

ArticleCureus2025

Beneficial Impact of Nutritional Therapy on Idiopathic Pulmonary Fibrosis.

Hideaki Yamakawa, Hiroki Ohta, Shintaro Sato, Hidekazu Matsushima

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hideaki YamakawaRespiratory Medicine, Saitama Red Cross Hospital, Saitama, JPN.
Hiroki OhtaRespiratory Medicine, Saitama Red Cross Hospital, Saitama, JPN.
Shintaro SatoRespiratory Medicine, Saitama Red Cross Hospital, Saitama, JPN.
Hidekazu MatsushimaRespiratory Medicine, Saitama Red Cross Hospital, Saitama, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although several studies have reported that poor nutritional status is associated with a worse prognosis in patients with interstitial lung disease (ILD), the beneficial impact of nutritional therapy has not yet been established. We report a case of idiopathic pulmonary fibrosis (IPF) in which nutritional therapy played an important role alongside drug therapy. A 71-year-old Japanese male was diagnosed with IPF and started on nintedanib. However, he experienced appetite loss, leading to significant weight loss and disease progression. Consequently, nintedanib was discontinued, and a dietitian introduced a high-fat, high-protein nutritional therapy. His condition improved, allowing nintedanib to be restarted after a period of cessation. Following multiple nutritional education sessions, his condition stabilized without further appetite loss. These findings suggest that when determining treatment strategies for patients with ILD, clinicians should incorporate appropriate nutritional management during long-term treatment with effective anti-ILD agents to optimize patient outcomes.

Indexed as

drug therapyidiopathic pulmonary fibrosisinterstitial lung diseasenintedanibnutrition therapy

Identifiers

PMID40062119
PMCPMC11889364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.